ENTASIS THERAPEUTICS LTD has a total of 83 patent applications. It decreased the IP activity by 86.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are KALA PHARMACEUTICALS INC, VIIV HEALTHCARE CO and VOKKHARDT LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | Australia | 6 | |
#3 | EPO (European Patent Office) | 6 | |
#4 | Singapore | 6 | |
#5 | Mexico | 5 | |
#6 | Taiwan | 5 | |
#7 | Canada | 4 | |
#8 | Hong Kong | 4 | |
#9 | Israel | 4 | |
#10 | Republic of Korea | 4 | |
#11 | Philippines | 4 | |
#12 | WIPO (World Intellectual Property Organization) | 4 | |
#13 | Brazil | 3 | |
#14 | China | 3 | |
#15 | EAPO (Eurasian Patent Organization) | 3 | |
#16 | Hungary | 3 | |
#17 | Montenegro | 3 | |
#18 | Serbia | 3 | |
#19 | New Zealand | 2 | |
#20 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Tommasi Ruben | 28 |
#2 | Verheijen Jeroen Cunera | 26 |
#3 | Durand-Reville Thomas Francois | 24 |
#4 | Zhou Fei | 21 |
#5 | Comita-Prevoir Janelle | 19 |
#6 | Basarab Gregory Steven | 19 |
#7 | Gowravaram Madhusudhan Reddy | 19 |
#8 | Mueller John | 18 |
#9 | Dejonge Boudewijn Lodewijk Maria | 17 |
#10 | Hauck Sheila Irene | 17 |
Publication | Filing date | Title |
---|---|---|
TW201823207A | Beta-lactamase inhibitor compounds | |
WO2017203266A1 | Combination therapy for treatment of resistant bacterial infections | |
CN107108624A | Combination treatment for treating drug resistant bacterial infections | |
EA033459B1 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | |
AU2013245399A1 | Heterobicyclic compounds as beta-lactamase inhibitors | |
AU2009305203A1 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections |